Literature DB >> 19715173

[Malignant lymphoma presented as left trigeminal neuralgia].

Miho Akaza1, Taiji Tsunemi, Nobuo Sanjo, Hiroaki Wakimoto, Daisuke Kobayashi, Hidehiro Mizusawa.   

Abstract

A male, 60 years of age, presented with transient left facial pain located within all three divisions of the trigeminal nerve. Magnetic resonance imaging (MRI) revealed a swollen left trigeminal nerve with gadolinium enhancement. Following schwannoma diagnosis, the patient received Gamma Knife radiosurgery, which proved effective against symptoms of neuralgia and enhanced lesions. A relapse of unsteadiness was noted 11 months after initial treatment. Furthermore, while MRI presented a normal trigeminal nerve, multiple enhanced white matter mass lesions around the lateral ventricles were observed. Lastly, pathological examinations revealed diffuse large B cell lymphomas. The administration of high-dose methotrexate followed with whole brain radiation therapy appeared to have remarkable effects. No recurrences were observed in a 30 month duration following secondary treatment. Malignant lymphoma may present as trigeminal neuralgia. The conclusions from our case report and another literature review follow a difficult to near impossible task of establishing a correct diagnosis without biopsy in the initial stages of trigeminal nerve tumors. Therefore, a careful MRI follow-up is necessary even if the tumors show a favorable response towards primary steroid treatment or Gamma Knife radiosurgery.

Entities:  

Mesh:

Year:  2009        PMID: 19715173     DOI: 10.5692/clinicalneurol.49.432

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  1 in total

1.  Long-term survival of diffuse large B cell lymphoma of the trigeminal region extending to the Meckel's cave treated by CHASER therapy: case report.

Authors:  Toshihide Tanaka; Naoki Kato; Kuniaki Itoh; Yuzuru Hasegawa
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-12-05       Impact factor: 1.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.